1011 related articles for article (PubMed ID: 28974267)
1. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
2. Musculoskeletal Responses to Exercise Plus Nutrition in Men with Prostate Cancer on Androgen Deprivation: A 12-Month RCT.
Dalla Via J; Owen PJ; Daly RM; Mundell NL; Livingston PM; Rantalainen T; Foulkes SJ; Millar JL; Murphy DG; Fraser SF
Med Sci Sports Exerc; 2021 Oct; 53(10):2054-2065. PubMed ID: 33867499
[TBL] [Abstract][Full Text] [Related]
3. Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial.
Mundell NL; Owen PJ; Dalla Via J; Macpherson H; Daly RM; Livingston PM; Rantalainen T; Foulkes S; Millar J; Murphy DG; Fraser SF
BMJ Open; 2022 Jun; 12(6):e060189. PubMed ID: 35750461
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
[TBL] [Abstract][Full Text] [Related]
5. Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol.
Baguley BJ; Skinner TL; Leveritt MD; Wright OR
BMC Cancer; 2017 Jan; 17(1):1. PubMed ID: 28049525
[TBL] [Abstract][Full Text] [Related]
6. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
7. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
8. The LIFTMOR-M (Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation for Men) trial: protocol for a semirandomised controlled trial of supervised targeted exercise to reduce risk of osteoporotic fracture in older men with low bone mass.
Harding AT; Weeks BK; Watson SL; Beck BR
BMJ Open; 2017 Jun; 7(6):e014951. PubMed ID: 28611110
[TBL] [Abstract][Full Text] [Related]
9. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.
Gardner JR; Livingston PM; Fraser SF
J Clin Oncol; 2014 Feb; 32(4):335-46. PubMed ID: 24344218
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.
Dalla Via J; Daly RM; Owen PJ; Mundell NL; Rantalainen T; Fraser SF
Bone; 2019 Oct; 127():367-375. PubMed ID: 31189088
[TBL] [Abstract][Full Text] [Related]
11. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
[TBL] [Abstract][Full Text] [Related]
12. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.
Nilsen TS; Raastad T; Skovlund E; Courneya KS; Langberg CW; Lilleby W; Fosså SD; Thorsen L
Acta Oncol; 2015 Nov; 54(10):1805-13. PubMed ID: 25927504
[TBL] [Abstract][Full Text] [Related]
13. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
[TBL] [Abstract][Full Text] [Related]
14. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy.
Kiwata JL; Dorff TB; Todd Schroeder E; Salem GJ; Lane CJ; Rice JC; Gross ME; Dieli-Conwright CM
BMJ Open; 2017 Jul; 7(7):e016910. PubMed ID: 28698349
[TBL] [Abstract][Full Text] [Related]
15. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
Lee CE; Leslie WD; Lau YK
BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
[TBL] [Abstract][Full Text] [Related]
17. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
Taaffe DR; Newton RU; Spry N; Joseph D; Chambers SK; Gardiner RA; Wall BA; Cormie P; Bolam KA; Galvão DA
Eur Urol; 2017 Aug; 72(2):293-299. PubMed ID: 28249801
[TBL] [Abstract][Full Text] [Related]
18. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.
Newton RU; Taaffe DR; Spry N; Gardiner RA; Levin G; Wall B; Joseph D; Chambers SK; Galvão DA
BMC Cancer; 2009 Jun; 9():210. PubMed ID: 19563641
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
20. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
